References of "Frankenne, F."
     in
Bookmark and Share    
Peer Reviewed
See detailQuantification of Angiogenesis of Embryonic Implantation Site by Image Analysis
Le Maire, Sophie; Blacher, Silvia ULg; Frankenne, F. et al

Conference (2003)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailEffects of 6-substituted 2-oxo-2H-1-benzopyran-3-carbowylic acide derivatives on cellular invasion in vitro
Kempen, I.; Frankenne, F.; Noël, Agnès ULg et al

Poster (2002, November 15)

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailEffect of matrigel on human extravillous trophoblasts differentiation: Modulation of protease pattern gene expression
Tarrade, A.; Goffin, Frédéric ULg; Munaut, Carine ULg et al

in Biology of Reproduction (2002), 67(5), 1628-1637

The human placenta is characterized by extensive trophoblast invasion of the uterus. Indeed, extravillous cytotrophoblast cells invade the. decidua and the upper third of uterine spiral arteries in the ... [more ▼]

The human placenta is characterized by extensive trophoblast invasion of the uterus. Indeed, extravillous cytotrophoblast cells invade the. decidua and the upper third of uterine spiral arteries in the myometrium. This invasion is reflected in situ by the expression of specific markers. In order to study this invasion process, we have established an in vitro culture model of human extravillous trophoblast isolated from first trimester chorionic villi. The aim of this study was to investigate the effect of a composite matrix, the Matrigel required for the culture of this homogenous population of extravillous trophoblasts (EVCT), on their in vitro differentiation. The effect of Matrigel was studied on different markers characterized by immunocytochemistry and by real-time polymerase chain reaction assay of transcripts. In addition, the expression of 12 different matrix metalloproteases and their inhibitors were investigated. We show that human extravillous cytotrophoblasts acquire an invasive phenotype on Matrigel associated with a specific pattern of protease gene expression. This in vitro model will be of interest to study the cellular mechanisms involved in abnormal trophoblast invasion observed in poor placentation and preeclampsia. [less ▲]

Detailed reference viewed: 14 (0 ULg)
Peer Reviewed
See detailEffects on in vitro and in vivo cellular invasion of two 6-(acetoxymethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives
Kempen, I.; Pochet, L.; Papapostolou, D. et al

Poster (2001, October 16)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailInfluence of Plasminogen Activator Inhibitor Type 1 on Choroidal Neovascularization
Lambert, Vincent ULg; Munaut, Carine ULg; Frankenne, F. et al

in FASEB Journal (2001), 15(6), 1021-7

High levels of the plasminogen activators, but also their inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic ... [more ▼]

High levels of the plasminogen activators, but also their inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies. [less ▲]

Detailed reference viewed: 34 (4 ULg)
Peer Reviewed
See detailComparaison de l’effet de deux coumarines sur l’inhibition de l’invasion cellulaire in vitro et in vivo
Kempen, I.; Pochet, L.; Papapostolu, D. et al

Poster (2001, January 26)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailType Iv Collagen Induces Matrix Metalloproteinase 2 Activation in Ht1080 Fibrosarcoma Cells
Maquoi, Erik ULg; Frankenne, F.; Noël, Agnès ULg et al

in Experimental Cell Research (2000), 261(2), 348-59

Matrix metalloproteinase 2 (MMP-2) activation has been described as a "master switch" which triggers tumor spread and metastatic progression. We show here that type IV collagen, a major component of ... [more ▼]

Matrix metalloproteinase 2 (MMP-2) activation has been described as a "master switch" which triggers tumor spread and metastatic progression. We show here that type IV collagen, a major component of basement membranes, promotes MMP-2 activation by HT1080 cells. When plated on plastic, HT1080 cells constitutively processed the 66-kDa pro-MMP-2 into a 62-kDa intermediate activated form, most probably through a membrane type (MT) 1 MMP-dependent mechanism. In the presence of type IV collagen, part of this intermediate form was further processed to fully activated 59-kDa MMP-2. This activation was prevented by tissue inhibitor of MMP (TIMP)-2 and a broad-spectrum hydroxamic acid-based synthetic MMP inhibitor (GI129471). Type IV collagen-mediated pro-MMP-2 activation did not involve either a transcriptional modulation of MMP-2, MT1-MMP, or TIMP-2 expression nor any alteration of MT1-MMP protein synthesis or processing. An inverse relationship between MMP-2 activation and the concentration of secreted TIMP-2 was observed. This is consistent with our previous report that TIMP-2 degradation is probably linked to the MT1-MMP-dependent MMP-2 activation mechanism. Because invasive tumor cells must breach basement membranes at different steps of the metastatic dissemination, the ability of HT1080 cells to activate pro-MMP-2 in the presence of type IV collagen might represent a key regulatory mechanism for the acquisition of an invasive potential. [less ▲]

Detailed reference viewed: 36 (0 ULg)
Full Text
Peer Reviewed
See detailMMP-2 and MMP-9-Linked Gelatinolytic Activity in the Sputum from Patients with Asthma and Chronic Obstructive Pulmonary Disease
Cataldo, Didier ULg; Munaut, Carine ULg; Noël, Agnès ULg et al

in International Archives of Allergy & Immunology (2000), 123(3), 259-67

BACKGROUND: The course of asthma and chronic obstructive pulmonary disease (COPD) is associated with bronchial morphological changes. Metalloproteinases are thought to play a role in these structural ... [more ▼]

BACKGROUND: The course of asthma and chronic obstructive pulmonary disease (COPD) is associated with bronchial morphological changes. Metalloproteinases are thought to play a role in these structural changes. METHODS: We studied the gelatinolytic activity present in the induced sputum from 20 patients with asthma, 20 with COPD and 19 healthy controls. The assessment of gelatinolytic activity was performed by quantitative zymography, and gelatinolytic species were identified by Western blot analysis. Tissue inhibitor of metalloproteinase-1 (TIMP-1) was detected by reverse zymography and ELISA. RESULTS: From zymography, we found significantly higher gelatinolytic activity linked to pro-matrix metalloproteinase-9 (pro-MMP-9) in the sputum from asthmatics (p < 0.0001) and COPD patients (p < 0.0001) compared to the control group. Furthermore, the activated form of MMP-9 (85 kD) was found in the sputum from 60% of asthmatics and 85% of COPD patients, but was absent in that of control subjects (p < 0.0001). Importantly, although less frequently detectable than pro-MMP-9, pro- MMP-2 (72 kD) was found more frequently in asthmatics (50%) than in control subjects (5%) (p < 0. 005). We also described two unusual gelatinolytic species of 45 and 120 kD and showed that they derived from MMP-9 according to their ability to bind gelatin and anti-MMP-9 antibody. Levels of TIMP-1 were higher in asthmatics (p < 0.05) and COPD patients (p < 0.05) than in controls. CONCLUSION: Asthmatics and COPD patients display an increased gelatinolytic activity linked to MMP-2 and MMP-9 and higher levels of TIMP-1 in their sputum. [less ▲]

Detailed reference viewed: 15 (1 ULg)
Peer Reviewed
See detailInhibition of cellular invasion by 3-chlorophenyl 6-(acetoxymethyl)-2-oxo-2H-1-benzopyran-3-carboxylate
Kempen, I.; Pochet, L.; Papapostulu, D. et al

Poster (2000, September)

Detailed reference viewed: 2 (0 ULg)
Peer Reviewed
See detailLes esters de l’acide 6-(acétoxyméthyl)-2-oxo-2H-1-benzopyrane-3-carboxylique en tant qu’agents antiinvasifs potentiels dans le traitement du cancer
Kempen, I.; Pochet, L.; Doucet, C. et al

Conference (2000, January 28)

Detailed reference viewed: 5 (2 ULg)
Full Text
Peer Reviewed
See detailHigh production of SPARC/osteonectin/BM-40 in mouse metastatic B16 melanoma cell lines
Kato, Y.; Frankenne, F.; Noël, Agnès ULg et al

in Pathology Oncology Research (2000), 6(1), 24-26

Abstract Production of SPARC/osteonectin/BM-40 was determined in mouse B16 melanoma clones BL6 and F10 (high metastatic) and F1 (low metastatic). SPARC was produced greater amount in BL6 and F10 than in ... [more ▼]

Abstract Production of SPARC/osteonectin/BM-40 was determined in mouse B16 melanoma clones BL6 and F10 (high metastatic) and F1 (low metastatic). SPARC was produced greater amount in BL6 and F10 than in F1 cells, showing a good agreement with their metastatic potentials. Moreover, SPARC production was not influenced by culture pH, even in the acidic conditions (= pH 5.9). Although tumor tissues show often low pH due to excessive amount of acidic metabolites such as lactate, most studies have been done in neutral pH. High SPARC production in the acidic medium, therefore, is thought to be an important potential for tumor invasive behaviour. [less ▲]

Peer Reviewed
See detailInhibition of cellular invasion by 3-chlorophenyl 6-(acetoxymethyl)-2-oxo-2H-1-benzopyran-3-carboxylate
Kempen, I.; Pochet, L.; Papapostulu, D. et al

in Pflügers Archiv : European Journal of Physiology (2000), 439

Detailed reference viewed: 4 (3 ULg)
Peer Reviewed
See detailMolecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy
Frankenne, F.; Noël, Agnès ULg; Bajou, Khalid ULg et al

in Expert Opinion on Therapeutic Targets (1999), 3(3), 469-48113

In the promotion of cancer progression, a classical role had previously been ascribed to the plasminogen activation system on the basis of urokinase plasminogen activator (uPA) proteolytic activity and ... [more ▼]

In the promotion of cancer progression, a classical role had previously been ascribed to the plasminogen activation system on the basis of urokinase plasminogen activator (uPA) proteolytic activity and plasminogen activation triggering a focalised pericellular activation cascade involving matrix metalloproteinases (MMPs). As a result, many pharmaceutical companies have undertaken the development of synthetic uPA inhibitors. However, during the last few years, data have accumulated that uPA, as well as urokinase-type plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1), are likely to play an essential role in tumour progression through non-proteolysis-related activities. Such activities endow them with new and likely key functions in tumour progression-associated events, such as cellular adhesion, migration, invasion and angiogenesis. Since these activities essentially depend upon protein-protein interactions, they represent new therapeutic targets. [less ▲]

Detailed reference viewed: 19 (6 ULg)